Comprehensive Forecast: Specific Antiviral Drugs For COVID 19 Market Share, Growth, and Opportunities Through 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Large Is the Specific Antiviral Drugs For COVID 19 Market Expected to Be in 2029?
The market size for specific antiviral drugs for covid 19 has witnessed rapid expansion in the recent past. Forecasted to increase from $13 billion in 2024, it is expected to reach $15.23 billion by 2025, with a compound annual growth rate (CAGR) of 17.1%. The historical period growth has been influenced by factors such as the increasing hospital admissions due to severe cases, increment of government grants for antiviral research, a growing preference for targeted therapeutics over generic treatments, heightened awareness about the need for early antiviral intervention, and escalating cooperative efforts between pharmaceutical companies.
The market size for specific antiviral drugs for covid 19 is anticipated to experience swift expansion in the coming years, ballooning to $28.43 billion in 2029 with a compound annual growth rate (CAGR) of 16.9%. The predicted growth during this period is linked to the heightened emphasis on pandemic readiness, increased instances of clinical trials, escalating demand for efficient COVID-19 treatment methods, rising occurrences of COVID-19 variations, and increased adoption of oral antiviral treatments. Expectations during the forecast period point towards innovations in broad-spectrum antiviral formulations, usage of artificial intelligence in drug discovery, advancements in personalized antiviral therapies, novel approaches in combination therapy, and the application of genomic data in addressing viral mutations.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24713&type=smp
What Are The Contributors To Demand In The Specific Antiviral Drugs For COVID 19 Market?
The escalation in COVID-19 instances is projected to fuel the expansion of the specific antiviral drugs market for COVID-19 going forward. When referring to COVID-19 cases, it denotes individuals who have been diagnosed positive for the SARS-CoV-2 virus that causes COVID-19. The surge in COVID-19 cases is attributable to the surfacing of new variants that transmit more readily and can partially dodge immunity from vaccinations or prior infections. The use of specific antiviral drugs for treating COVID-19 can help mitigate the severity and length of the ailment, thereby improving patient recovery rates and lessening the overall impact of COVID-19 instances. For example, as per data from the US-based government body, the Centers for Disease Control and Prevention, in May 2023, the average number of contributing conditions listed in COVID-19 death cases where additional causes of death were included, rose from 4.2 in 2021 to 4.5 in 2022. Consequently, the rapid surge in COVID-19 cases propels the expansion of the specific antiviral drugs market for COVID-19.
What Segmentation Categories Are Included In The Specific Antiviral Drugs For COVID 19 Market Analysis?
The specific antiviral drugs for covid 19 market covered in this report is segmented –
1) By Type: Tablet, Injection
2) By Indication: Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment
3) By Drug Class: Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies
4) By Route Of Administration: Oral, Intravenous, Subcutaneous, Inhalation
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments
1) By Tablet: Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets
2) By Injection: Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections
What Upcoming Trends Are Expected To Impact The Specific Antiviral Drugs For COVID 19 Market Globally?
Leading corporations serving the COVID-19 specific antiviral drug market are striving to devise innovative therapeutic solutions, including oral antiviral treatments, to boost the efficacy and attainability of treatment. Oral antiviral treatments are drugs consumed orally designed to suppress the multiplication of viruses like COVID-19, thus presenting an efficient and user-friendly treatment alternative. For example, Lupin Limited, a pharmaceutical organization based in India, unveiled its antiviral medication, Molnupiravir, under the brand Molnulup in January 2022, aimed at treating adults with COVID-19 at high risk. This orally administered drug is designed for adults exhibiting mild to moderate COVID-19 symptoms, who are susceptible to progression to severe disease. Molnupiravir functions by curbing the replication of the SARS-CoV-2 virus, assisting in reducing viral burden and disease severity. It demonstrates maximum effectiveness when initiated within five days from the commencement of symptoms and is particularly advantageous for individuals having comorbid conditions like obesity, old age, diabetes, or heart disease.
Who Are The Top-Ranked Companies In The Specific Antiviral Drugs For COVID 19 Market Today?
Major companies operating in the specific antiviral drugs for covid 19 market are Pfizer Inc., Johnson and Johnson, Roche Holding AG, Merck And Co. Inc., Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Limited, Beximco Pharmaceuticals Limited, BioCryst Pharmaceuticals Inc., Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Aligos Therapeutics Inc., Synairgen plc
Get The Full Report Here:
How Is Specific Antiviral Drugs For COVID 19 Market Adoption Varying Across Different Regions And Sectors?
North America was the largest region in the specific antiviral drugs for COVID 19 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specific antiviral drugs for covid 19 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=24713&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
